We are excited to announce that we are enrolling patients with Non-Advanced Systemic Mastocytosis in an ongoing, global clinical trial called the Summit Study.
Recruitment for the study will continue into the second quarter of 2025.
The Summit Study is a randomized, double-blind, placebo-controlled Phase 2 trial comparing the safety and efficacy of bezuclastinib (CGT9486) versus placebo. Bezuclastinib is a highly selective and potent KIT D816V mutant inhibitor that is molecularly designed to avoid CNS penetration. The clinical data from Part 1 of the ongoing Summit trial was presented at AAAAI and EHA2024.
For patient referrals and screening, please contact Dr. Richard Herrscher at AIR Care MD, 972-473-7545 to discuss potential patient eligibility and referrals for this study.
The sponsor of this study, Cogent Biosciences, offers patient and caregiver reimbursement for travel and meal expenses incurred due to study participation. More information about the Summit Study is available at the following website: https://clinicaltrials.gov/ct2/show/NCT05186753.